Provided is a method for treating a subject, comprising contacting the subject with a drug delivery device comprising a nauseogenic compound, wherein the drug delivery device administers the nauseogenic compound to the subject, and the contacting occurs after an administration of the drug delivery device comprising the nauseogenic compound to a human patient population during a first clinical trial； and wherein less than 10% of the human patient population, to whom the drug delivery device comprising the nauseogenic compound was administered, reported having nausea and/or vomiting during the first clinical trial.
